TY -的T1 -包含bedaquiline方案和delamanid相比,耐药结核病患者bedaquiline JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01181 -2019欧元六世- 55 - 1 SP - 1901181 AU Olayanju Olatunde盟——提出Aliasgar AU - Limberis,杰森盟——Dheda Keertan Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/55/1/1901181.abstract N2 -有有限的数据结合delamanid和bedaquiline耐药结核病(DR-TB)方案。未来的长期结果数据,包括在感染艾滋病毒的人,都不可用。我们前瞻性随访122南非患者(感染艾滋病毒的52.5%)DR-TB和不良预后特征在2014和2018之间。我们检查的结果和安全在那些收到bedaquiline-based养生法(n = 82)相比,那些获得bedaquiline-delamanid组合方案(n = 40)。没有显著差异在6个月的文化转换(分别为92.5%和81.8%;p = 0.26)和18个月的有利结果率(分别为63.4%和67.5%;p = 0.66) bedaquiline与bedaquiline-delamanid组合组,尽管后者有更高级的耐药性(3.7%比22.5%抗至少五药物;p = 0.001)和预处理失败率更高(12.2%比52.5%预处理耐多药结核病治疗失败;术中,0.001)。虽然延长QT间隔的比例修正使用Fridericia公式组合组高(在60 ms从基线(p = 0.001)或在450 ms治疗期间(p = 0.001),没有症状的情况下或在两组药物取款。感染艾滋病毒的患者的结果相似。A bedaquiline–delamanid combination regimen showed comparable long-term safety compared to a bedaquiline-based regimen in patients with DR-TB, irrespective of HIV status. These data inform regimen selection in patients with DR-TB from TB-endemic settings.A bedaquiline–delamanid combination regimen in drug-resistant tuberculosis patients with poor prognostic factors showed comparable efficacy and safety to those in a bedaquiline-based regimen http://bit.ly/32j7Fyo ER -